Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

European survey evaluating the use of azithromycin in neonates

Pansieri, C., Pandolfini, C., Elie, V., Turner, M., Kotecha, S. ORCID: https://orcid.org/0000-0003-3535-7627, Bonati, M. and Jacqz-Aigrain, E. 2015. European survey evaluating the use of azithromycin in neonates. Fundamental and Clinical Pharmacology 29 (S1) , p. 43. 10.1111/fcp.12106

Full text not available from this repository.

Abstract

Background: The role of Ureaplasma Urealyticum (UU) colonisation of the lungs remains controversial in the occurrence of bronchopulmonarydysplasia (BPD) of prematurity. The present European survey was conducted between April and July 2012, as part of the FP7-TINN2-project (Treat Infections in Neonates 2, www.tinn2-project.org). Aims and methods: It aimed to evaluate the position of neonatologists regarding the role of UU as a risk factor for BPD, use of azithromycin (AZY) for the prevention of BPD and factors that influence this practice in European neonatal intensive care units (NICUs). It was conducted using an online questionnaire of 64 questions. Results: 167 questionnaires from twenty-eight European countries were analyzed. All responders confirmed that the two major risk factors for BPD were prematurity ≤28weeks and high oxygen requirements. Various macrolides are used in Europe to treat or prevent Ureaplasma colonisation. Among them, AZY has antibacterial, anti-inflammatory and immuno-modulating properties, is employed throughout Europe (27% NICUs in 12countries), usually administered at a starting dose of 10mg/kg (60% of NICUs), followed by a maintenance dose of 5mg/kg/day (43% of NICUs). For 10 days. 78% of the NICUs were interested in the TINN2-project to evaluate the efficacy and safety of AZY versus placebo in reducing the risk of BPD in premature babies. For most neonatologists, newborns between 23 and 28weeks gestational age would be the best group of premature babies to be included in the trial.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Wiley
ISSN: 0767-3981
Last Modified: 02 Nov 2022 11:28
URI: https://orca.cardiff.ac.uk/id/eprint/102111

Actions (repository staff only)

Edit Item Edit Item